Nasus Pharma will present at upcoming investor conferences in February and March, focusing on its intranasal drug development.
Quiver AI Summary
Nasus Pharma Ltd., a clinical-stage pharmaceutical company specializing in innovative intranasal products, has announced its participation in several upcoming investor conferences in February and March 2026. CEO Dan Teleman will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, the BIO Investment & Growth Summit on March 2, and the Citizens Life Sciences Conference on March 11, with opportunities for one-on-one meetings. The company is developing intranasal powder products, including NS002, a needle-free alternative to traditional Epinephrine autoinjectors for treating anaphylaxis, leveraging its proprietary technology for rapid and easy drug delivery. For more information, interested parties can visit their website or contact their investor relations.
Potential Positives
- Participation in multiple upcoming investor conferences indicates proactive engagement with the investment community, potentially increasing visibility and interest in the company's development efforts.
- The presentation of the innovative intranasal powder products, particularly the needle-free Epinephrine candidate, highlights the company's focus on addressing acute medical conditions, showcasing its commitment to patient-centered solutions.
- Nasus Pharma’s proprietary powder-based intranasal technology may attract attention for its potential advantages over traditional methods, positioning the company favorably within the pharmaceutical industry.
Potential Negatives
- Company is still in clinical stages, indicating a lack of fully developed products available on the market.
- Dependence on upcoming investor conferences for visibility may suggest potential challenges in attracting investment outside these events.
- Lack of detailed results or advancements in product development, particularly regarding NS002, might raise concerns about the company's progress and viability.
FAQ
What conferences will Nasus Pharma participate in?
Nasus Pharma will participate in the Oppenheimer Healthcare Conference, BIO Investment & Growth Summit, and Citizens Life Sciences Conference.
Who is the speaker at the investor conferences?
Dan Teleman, the Chief Executive Officer of Nasus Pharma, will be the speaker at all scheduled conferences.
How can I register for the conferences?
You can register for the Oppenheimer Healthcare Conference through the provided link in the press release.
What is Nasus Pharma developing?
Nasus Pharma is developing intranasal powder products, including a needle-free Epinephrine alternative for anaphylaxis management.
Where can I find more information about Nasus Pharma?
For more information, visit the Nasus Pharma website at www.nasuspharma.com or follow them on Twitter and LinkedIn.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NSRX Hedge Fund Activity
We have seen 0 institutional investors add shares of $NSRX stock to their portfolio, and 1 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG removed 863 shares (-69.5%) from their portfolio in Q4 2025, for an estimated $7,896
- MORGAN STANLEY added 0 shares (+0.0%) to their portfolio in Q4 2025, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$NSRX Analyst Ratings
Wall Street analysts have issued reports on $NSRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Laidlaw & Co. issued a "Buy" rating on 09/29/2025
To track analyst ratings and price targets for $NSRX, check out Quiver Quantitative's $NSRX forecast page.
$NSRX Price Targets
Multiple analysts have issued price targets for $NSRX recently. We have seen 2 analysts offer price targets for $NSRX in the last 6 months, with a median target of $20.5.
Here are some recent targets:
- Jason Butler from Citizens set a target price of $19.0 on 12/18/2025
- Yale Jen from Laidlaw & Co. set a target price of $22.0 on 09/29/2025
Full Release
TEL AVIV, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Company management will participate in upcoming investor conferences in February and March.
Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Date and time: February 25, 2026, 1:20 p.m. ET
- Location: Virtual ( register here: https://event.summitcast.com/view/CTtthLh2Bi2D9aYoKpvtEv/KoYPJS8x3zqMuXPHfEHoSY )
- Format: Company presentation
- Speaker: Dan Teleman, Chief Executive Officer
BIO Investment & Growth Summit
- Date and time: March 2, 2026, 10:15 a.m. ET
- Location: Miami, FL
- Format: Company presentation
- Speaker: Dan Teleman, Chief Executive Officer
Citizens Life Sciences Conference
- Date and time: March 11, 2026, 3:25 p.m. ET
- Location: Miami, FL
- Format: Company presentation
- Speaker: Dan Teleman, Chief Executive Officer
Nasus management will be available for one-on-one meetings during the conferences. Interested parties should contact their conference representative to arrange a meeting.
About Nasus Pharma
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’ intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus’ proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit
www.nasuspharma.com
or follow on
Twitter (X)
or
LinkedIn
.
Company Contact
Nasus Pharma Ltd.
[email protected]
Investor Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
[email protected]
